NanoPharmaceuticals Logo


NanoPharmaceuticals’ scientists, either individually or collectively, have written over 1,000 peer-reviewed articles. Below is a list of the 24 most relevant publications relating to NanoPharmaceuticals’ current activities.

Background Information

Davis PJ, et al. Nongenomic Actions of Thyroid Hormone: The Integrin Component. Physiol Rev. 2021 Jan 1;101(1):319-352.

Sudha T, et al. Nano-Targeting of Thyrointegrin αvβ3 Receptor in Solid Tumors and Impact on Radiosensitization. Radiation Res. 2021 Jul 14. doi: 10.1667/RADE-21-00031.1.

Davis PJ, et al. Coronaviruses and Integrin αvβ3: Does Thyroid Hormone Modify the Relationship? Endocr Res. 2020 Aug;45(3):210-215.

Debreli Coskun M, et al. αvβ3 Integrin Antagonists Enhance Chemotherapy Response in an Orthotopic Pancreatic Cancer Model. Front Pharmacol. 2020 Feb 27;11:95.

Sami SA, et al. Current and Future Molecular Targets for Acute Myeloid Leukemia Therapy. Curr Treat Options Oncol. 2020 Jan 13;21(1):3. doi: 10.1007/s11864-019-0694-6.

Pastor ER, Mousa SA. Current management of neuroblastoma and future direction. Crit Rev Oncol Hematol. 2019 Jun;138:38-43.

Rajabi M, et al. Synthesis of new analogs of tetraiodothyroacetic acid (tetrac) as novel angiogenesis inhibitors for treatment of cancer. Bioorganic & medicinal chemistry letters. 2018;28(7):1223-7.

Mousa SA, et al. Contributions of thyroid hormone to cancer metastasis. Biomedicines. 2018;6(3):89.

TAT Molecules in GBM

Rajabi M, et al. Triazole Modified Tetraiodothyroacetic Acid Conjugated to Polyethylene Glycol: High Affinity Thyrointegrin αvβ3 Antagonist with Potent Anticancer Activities in Glioblastoma Multiforme. Bioconjug Chem. 2019 Dec 18;30(12):3087-3097.

Hay B, et al. New Thyrointegrin αvβ3 Antagonist with a Scalable Synthesis, Brain Penetration, and Potent Activity against Glioblastoma Multiforme. J. Medicinal Chemistry; 2021 Apr 22. doi: 10.1021/acs.jmedchem.1c00350.

Mousa, S., et al. Novel thyrointegrin αvβ3 antagonist in the treatment of glioblastoma multiforme. Cancer Research, 2019; 79: p. 1300.

Godugu K, et al. Anti-Cancer Activities of Thyrointegrin αvβ3 Antagonist Mono- and Bis-Triazole Tetraiodothyroacetic Acid Conjugated via Polyethylene Glycols in Glioblastoma. Cancers (Basel). 2021 Jun 3;13(11):2780. doi: 10.3390/cancers13112780.

Neuroendocrine Cancer – Neuroblastoma (BG-P-TAT)

Karakus OO, et al. Design, synthesis, and biological evaluation of novel bifunctional thyrointegrin antagonists for neuroblastoma. Bioorg Med Chem. 2021 Jul 15;42:116250. doi: 10.1016/j.bmc.2021.116250.

Karakus OO, et al. Dual Targeting of Norepinephrine Transporter (NET) Function and Thyrointegrin αvβ3 Receptors in the Treatment of Neuroblastoma. J Med Chem. 2020 Jul 23;63(14):7653-7662.

Karakus OO, et al. Discovery of Dual Targeting PEGylated BG-P1600-TAT to Norepinephrine Transporter (NET) and Thyrointegrin αvβ3 in the Treatment of Neuroblastoma: Broad Spectrum Anti-Angiogenesis and Anti-Cancer Activities. Bioorganic & Medicinal Chemistry; 2021 August 1;43:116278.

TAT Molecules in AML

Darwish NE, et al. Novel Thyrointegrin αvβ3 Antagonist (fb-PMT) with Potent Affinity in the Treatment of Acute Myeloid Leukemia. Blood Advances 2021; under review.

Mousa SA, et al. Novel Thyrointegrin αvβ3 Antagonist (fb-PMT) for the Effective Management of Acute Myeloid Leukemia. Blood.2020; 136 (Supplement 1): 5. doi: 10.1182/blood-2020-141628.

Sudha T, et al. Novel Polyethylene Glycol-Conjugated Triazole Derivative with High Thyrointegrin αvβ3 Affinity in Acute Myeloid Leukemia Management. Cancers; 13(16):4070. doi: 10.3390/cancers13164070.

Nano-Targeted Delivery

Godugu K, et al. Nano Diaminopropane tetrac and integrin αvβ3 expression in different cancer types: Anti-cancer efficacy and safety. Cancer Treat Res Commun. 2021 May 13;28:100395. doi: 10.1016/j.ctarc.2021.100395.

Sudha T, et al.. Nano-Targeting of Thyrointegrin αvβ3 Receptor in Solid Tumors and Impact on Radiosensitization. Radiation Res. 2021 Jul 14. doi: 10.1667/RADE-21-00031.1.

Karakus OO, et al. Norepinephrine Transporter Analogue Benzylguanidine Conjugated Nanoparticles in the Treatment of Neuroblastoma. Nanomedicine; 2021 Oct 15.

Li W, et al. Pharmacokinetics, Biodistribution, and Anti-Angiogenesis Efficacy of Diamino Propane Tetraiodothyroacetic Acid-conjugated Biodegradable Polymeric Nanoparticle. Sci Rep. 2019 Jun 21;9(1):9006.

Sudha T, et al. Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac. Int J Nanomedicine. 2017;12:1305-1315.

Sudha T, et al. Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac. Nanomedicine (Lond). 2017 Feb;12(3):195-205.